CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 84% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Trade IDEAYA Biosciences, Inc. - IDYA CFD

25.35
3.94%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.08
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.025457 %
Charges from borrowed part ($-1.02)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.025457%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003235 %
Charges from borrowed part ($0.13)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
0.003235%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 20%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

IDEAYA Biosciences Inc ESG Risk Ratings

High Medium Low Negligible

‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 24.39
Open* 24.46
1-Year Change* 107.11%
Day's Range* 24.25 - 25.47
52 wk Range 9.00-24.96
Average Volume (10 days) 574.81K
Average Volume (3 months) 14.88M
Market Cap 1.40B
P/E Ratio -100.00K
Shares Outstanding 57.29M
Revenue 47.45M
EPS -1.52
Dividend (Yield %) N/A
Beta 0.84
Next Earnings Date Aug 14, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Jun 6, 2023 24.39 0.42 1.75% 23.97 24.53 23.93
Jun 5, 2023 24.34 -0.16 -0.65% 24.50 24.90 24.22
Jun 2, 2023 24.82 1.12 4.73% 23.70 24.84 23.48
Jun 1, 2023 23.87 1.36 6.04% 22.51 23.90 22.35
May 31, 2023 22.81 1.03 4.73% 21.78 22.95 21.78
May 30, 2023 21.83 0.06 0.28% 21.77 22.58 21.77
May 26, 2023 22.19 0.96 4.52% 21.23 22.37 21.23
May 25, 2023 21.60 -0.77 -3.44% 22.37 22.41 21.51
May 24, 2023 22.59 -0.28 -1.22% 22.87 22.87 21.57
May 23, 2023 21.85 -0.37 -1.67% 22.22 22.41 21.73
May 22, 2023 22.19 0.68 3.16% 21.51 22.97 21.47
May 19, 2023 21.74 0.28 1.30% 21.46 21.95 21.16
May 18, 2023 21.15 0.17 0.81% 20.98 21.34 20.81
May 17, 2023 21.13 -0.14 -0.66% 21.27 21.47 20.87
May 16, 2023 21.34 0.32 1.52% 21.02 21.73 20.85
May 15, 2023 21.62 0.15 0.70% 21.47 22.35 21.32
May 12, 2023 21.37 0.60 2.89% 20.77 21.46 20.77
May 11, 2023 21.41 -0.73 -3.30% 22.14 22.14 20.91
May 10, 2023 22.39 -0.17 -0.75% 22.56 22.74 21.92
May 9, 2023 22.25 3.11 16.25% 19.14 22.33 18.97

IDEAYA Biosciences, Inc. Events

Time (UTC) Country Event
Thursday, June 15, 2023

Time (UTC)

17:40

Country

US

Event

IDEAYA Biosciences Inc at Goldman Sachs Healthcare Conference
IDEAYA Biosciences Inc at Goldman Sachs Healthcare Conference

Forecast

-

Previous

-
Monday, August 14, 2023

Time (UTC)

10:00

Country

US

Event

Q2 2023 IDEAYA Biosciences Inc Earnings Release
Q2 2023 IDEAYA Biosciences Inc Earnings Release

Forecast

-

Previous

-
Monday, November 6, 2023

Time (UTC)

11:00

Country

US

Event

Q3 2023 IDEAYA Biosciences Inc Earnings Release
Q3 2023 IDEAYA Biosciences Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 50.931 27.941 19.538 0 0
Total Operating Expense 113.433 78.209 54.882 44.271 36.417
Selling/General/Admin. Expenses, Total 23.897 20.051 15.184 9.952 4.668
Research & Development 89.536 58.158 39.698 34.319 31.749
Operating Income -62.502 -50.268 -35.344 -44.271 -36.417
Interest Income (Expense), Net Non-Operating 3.847 0.506 0.849 2.288 1.994
Other, Net 0.008 0.077
Net Income Before Taxes -58.655 -49.762 -34.495 -41.975 -34.346
Net Income After Taxes -58.655 -49.762 -34.495 -41.975 -34.346
Net Income Before Extra. Items -58.655 -49.762 -34.495 -41.975 -34.346
Net Income -58.655 -49.762 -34.495 -41.975 -34.346
Income Available to Common Excl. Extra. Items -58.655 -49.762 -34.495 -41.975 -34.346
Income Available to Common Incl. Extra. Items -58.655 -49.762 -34.495 -41.975 -34.346
Diluted Net Income -58.655 -49.762 -34.495 -41.975 -34.346
Diluted Weighted Average Shares 41.4447 35.2524 24.7218 12.497 19.4786
Diluted EPS Excluding Extraordinary Items -1.41526 -1.41159 -1.39533 -3.35882 -1.76326
Dividends per Share - Common Stock Primary Issue 0
Diluted Normalized EPS -1.41526 -1.41159 -1.39533 -3.35882 -1.76326
Revenue 50.931 27.941 19.538
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Total revenue 7.88 4.022 29.699 5.851 11.359
Revenue 7.88 4.022 29.699 5.851 11.359
Total Operating Expense 34.159 30.465 29.039 28.35 25.579
Selling/General/Admin. Expenses, Total 6.3 5.752 6.667 5.554 5.923
Research & Development 27.859 24.713 22.372 22.796 19.656
Operating Income -26.279 -26.443 0.66 -22.499 -14.22
Interest Income (Expense), Net Non-Operating 2.639 2.242 0.955 0.443 0.207
Net Income Before Taxes -23.64 -24.201 1.615 -22.056 -14.013
Net Income After Taxes -23.64 -24.201 1.615 -22.056 -14.013
Net Income Before Extra. Items -23.64 -24.201 1.615 -22.056 -14.013
Net Income -23.64 -24.201 1.615 -22.056 -14.013
Income Available to Common Excl. Extra. Items -23.64 -24.201 1.615 -22.056 -14.013
Income Available to Common Incl. Extra. Items -23.64 -24.201 1.615 -22.056 -14.013
Diluted Net Income -23.64 -24.201 1.615 -22.056 -14.013
Diluted Weighted Average Shares 48.3701 48.2055 41.1096 38.661 38.592
Diluted EPS Excluding Extraordinary Items -0.48873 -0.50204 0.03929 -0.5705 -0.36311
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.48873 -0.50204 0.03929 -0.5705 -0.36311
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 370.454 250.996 288.605 101.654 90.667
Cash and Short Term Investments 364.829 246.77 283.585 98.956 89.961
Cash & Equivalents 68.632 92.046 72.037 34.067 20.505
Short Term Investments 296.197 154.724 211.548 64.889 69.456
Prepaid Expenses 5.414 3.123 3.143 2.698 0.706
Total Assets 387.969 381.347 298.269 113.001 96.541
Property/Plant/Equipment, Total - Net 8.993 8.661 9.476 9.699 5.152
Property/Plant/Equipment, Total - Gross 16.546 14.258 13.37 12.215 6.435
Accumulated Depreciation, Total -7.553 -5.597 -3.894 -2.516 -1.283
Other Long Term Assets, Total 0.205 0.397 0.188 0.122 0.722
Total Current Liabilities 31.718 45.159 38.64 6.94 5.413
Accounts Payable 4.28 2.1 0.953 0.709 1.417
Accrued Expenses 18.87 14.019 10.056 6.168 3.583
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 8.568 29.04 27.631 0.063 0.413
Total Liabilities 38.514 79.833 99.995 12.601 7.098
Total Long Term Debt 0 0 0 0 0
Long Term Debt 0
Other Liabilities, Total 6.796 34.674 61.355 5.661 1.685
Total Equity 349.455 301.514 198.274 100.4 89.443
Redeemable Preferred Stock 0 97.656
Preferred Stock - Non Redeemable, Net 0 40.735
Common Stock 0.005 0.004 0.003 0.002 0
Additional Paid-In Capital 587.724 478.97 325.25 192.824 1.599
Retained Earnings (Accumulated Deficit) -235.403 -176.748 -126.986 -92.491 -50.516
Other Equity, Total -2.871 -0.712 0.007 0.065 -0.031
Total Liabilities & Shareholders’ Equity 387.969 381.347 298.269 113.001 96.541
Total Common Shares Outstanding 48.1932 38.5331 29.5372 20.3395 19.4786
Long Term Investments 8.317 121.293 1.526
Total Receivables, Net 0.211 1.103 1.877
Accounts Receivable - Trade, Net 0.211 1.103 1.877
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Total Current Assets 343.958 370.454 393.437 272.189 256.049
Cash and Short Term Investments 339.47 364.829 386.244 268.62 252.599
Cash & Equivalents 67.237 68.632 101.954 49.106 55.291
Short Term Investments 272.233 296.197 284.29 219.514 197.308
Total Receivables, Net 0.468 0.211 3.449 0.288 0.697
Accounts Receivable - Trade, Net 0.468 0.211 3.449 0.288 0.697
Prepaid Expenses 4.02 5.414 3.744 3.281 2.753
Total Assets 364.746 387.969 410.907 338.007 358.867
Property/Plant/Equipment, Total - Net 8.828 8.993 9.527 10.367 8.828
Property/Plant/Equipment, Total - Gross 16.915 16.546 16.527 16.813 14.883
Accumulated Depreciation, Total -8.087 -7.553 -7 -6.446 -6.055
Long Term Investments 11.74 8.317 7.691 55.171 93.628
Other Long Term Assets, Total 0.22 0.205 0.252 0.28 0.362
Total Current Liabilities 29.82 31.718 32.727 58.089 56.957
Accounts Payable 4.376 4.28 3.645 4.227 3.364
Accrued Expenses 19.189 18.87 18.815 18.013 14.369
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 6.255 8.568 10.267 35.849 39.224
Total Liabilities 30.936 38.514 42.138 68.686 70.2
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 1.116 6.796 9.411 10.597 13.243
Total Equity 333.81 349.455 368.769 269.321 288.667
Common Stock 0.005 0.005 0.005 0.004 0.004
Additional Paid-In Capital 594.253 587.724 583.968 485.763 482.228
Retained Earnings (Accumulated Deficit) -259.043 -235.403 -211.202 -212.817 -190.761
Other Equity, Total -1.405 -2.871 -4.002 -3.629 -2.804
Total Liabilities & Shareholders’ Equity 364.746 387.969 410.907 338.007 358.867
Total Common Shares Outstanding 48.3904 48.1932 48.0904 38.704 38.6399
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -58.655 -49.762 -34.495 -41.975 -34.346
Cash From Operating Activities -87.175 -55.779 55.463 -39.313 -27.62
Cash From Operating Activities 2.101 1.725 1.381 1.245 0.886
Non-Cash Items 10.934 10.071 4.171 1.701 4.186
Cash Taxes Paid 0 0.004 0.001 0.001 0.001
Cash Interest Paid 0.06 0.071 0.082 0.091 0.099
Changes in Working Capital -41.555 -17.813 84.406 -0.284 1.654
Cash From Investing Activities -33.404 -69.666 -146.243 2.265 -63.179
Capital Expenditures -3.443 -2.644 -0.493 -1.353 -1.708
Other Investing Cash Flow Items, Total -29.961 -67.022 -145.75 3.618 -61.471
Cash From Financing Activities 97.165 145.454 128.75 50.61 105.378
Financing Cash Flow Items 0 0 19.988 0 -0.071
Issuance (Retirement) of Stock, Net 97.165 145.454 108.762 50.61 105.449
Net Change in Cash -23.414 20.009 37.97 13.562 14.579
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -23.64 -58.655 -34.454 -36.069 -14.013
Cash From Operating Activities -27.842 -87.175 -63.805 -39.639 -19.647
Cash From Operating Activities 0.588 2.101 1.543 0.974 0.464
Non-Cash Items 2.102 10.934 9.086 6.167 2.954
Cash Taxes Paid 0 0 0
Cash Interest Paid 0.013 0.06 0.046 0.032 0.016
Changes in Working Capital -6.892 -41.555 -39.98 -10.711 -9.052
Cash From Investing Activities 23.521 -33.404 -23.128 -4.445 -17.761
Capital Expenditures -0.043 -3.443 -3.443 -2.342 -0.401
Other Investing Cash Flow Items, Total 23.564 -29.961 -19.685 -2.103 -17.36
Cash From Financing Activities 2.926 97.165 96.841 1.144 0.653
Issuance (Retirement) of Stock, Net 2.926 97.165 96.841 1.144 0.653
Net Change in Cash -1.395 -23.414 9.908 -42.94 -36.755
Financing Cash Flow Items 0
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Avidity Partners Management LP Hedge Fund 6.4119 3673400 -151400 2023-03-31 LOW
Logos Global Management LLC Investment Advisor 6.2838 3600000 -300000 2023-03-31 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 5.4914 3146021 -21258 2023-03-31 LOW
Federated Hermes Global Investment Management Corp. Investment Advisor/Hedge Fund 5 2864500 0 2023-03-31 LOW
Adage Capital Management, L.P. Hedge Fund 4.6719 2676559 75000 2023-03-31 MED
Canaan Partners Venture Capital 4.6443 2660713 0 2023-03-31 LOW
BVF Partners L.P. Hedge Fund 4.2854 2455089 250000 2023-03-31 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 4.0391 2314036 31196 2023-03-31 LOW
Boxer Capital, L.L.C. Hedge Fund 3.845 2202812 0 2023-03-31 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 3.6905 2114317 -208324 2023-03-31 LOW
Deerfield Management Company, L.P. Hedge Fund 3.0435 1743628 0 2023-03-31 MED
T. Rowe Price Associates, Inc. Investment Advisor 2.5274 1447964 -199029 2023-03-31 LOW
Dimensional Fund Advisors, L.P. Investment Advisor/Hedge Fund 1.8091 1036451 309135 2023-03-31 LOW
Citadel Advisors LLC Hedge Fund 1.7649 1011116 124257 2023-03-31 HIGH
5AM Ventures Venture Capital 1.516 868520 -327778 2023-03-31 MED
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.501 859934 54033 2023-03-31 LOW
Platinum Asset Management Investment Advisor/Hedge Fund 1.4584 835521 4984 2023-03-31 LOW
Baker Bros. Advisors LP Hedge Fund 1.4536 832769 -835586 2023-03-31 LOW
Hata (Yujiro S.) Individual Investor 1.1833 677887 11601 2023-04-12 LOW
Janus Henderson Investors Investment Advisor/Hedge Fund 1.1484 657897 -26080 2023-03-31 LOW

Start a global, multi-asset portfolio with an award-winning platform

Desktop

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

IDEAYA Biosciences, Inc. Company profile

About Ideaya Biosciences Inc

IDEAYA Biosciences, Inc. is a synthetic lethality-focused precision medicine company. The Company focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The Company’s product candidate is IDE196, a protein kinase C (PKC), inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes multiple synthetic lethality programs, including against methionine adenosyltransferase 2a (MAT2A) in tumor cells having methylthioadenosine phosphorylase (MTAP) gene deletion; Pol-theta, in tumors with genetic mutations in homologous recombination deficiency (HRD), including breast carcinoma (BRCA ) mutations; poly adenosine diphosphate-ribose glycohydrolase (PARG), in tumors with genetic mutations in BRCA or base excision repair, and Werner Helicase, in high microsatellite instability tumors (MSI) tumors.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Ideaya Biosciences Inc revenues increased 43% to $27.9M. Net loss increased 44% to $49.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balanci increase of 42% to $54.7M (expense), Stock-based Compensation in SGA increase from $1.2M to $4.7M (expense).

Industry: Biotechnology & Medical Research (NEC)

7000 Shoreline Ct Ste 350
SOUTH SAN FRANCISCO
CALIFORNIA 94080-7604
US

Income Statement

  • Annual
  • Quarterly

People also watch

Gold

1,946.14 Price
-0.880% 1D Chg, %
Long position overnight fee -0.0090%
Short position overnight fee 0.0008%
Overnight fee time 21:00 (UTC)
Spread 0.30

Oil - Crude

72.55 Price
+1.400% 1D Chg, %
Long position overnight fee -0.0156%
Short position overnight fee -0.0063%
Overnight fee time 21:00 (UTC)
Spread 0.03

US100

14,309.80 Price
-1.770% 1D Chg, %
Long position overnight fee -0.0255%
Short position overnight fee 0.0032%
Overnight fee time 21:00 (UTC)
Spread 1.8

BTC/USD

26,440.10 Price
-2.000% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 60.00

Still looking for a broker you can trust?

Join the 535.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading